Overview

Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma

Status:
Not yet recruiting
Trial end date:
2023-07-19
Target enrollment:
Participant gender:
Summary
The investigators hypothesize that combination anlotinib with toripalimab will improve progression-free survival relative to historical controls in patients with Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma.
Phase:
Phase 2
Details
Lead Sponsor:
Di Wu
First Hospital of Jilin University